Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the development of so-called “me too” drugs. For example, Rep. Donna Shalala was recently quoted as saying:  “I think it actually will reduce me-too drugs … I think [pharmaceutical companies] are going to…

Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event…

For the FDA, engagement with patients, caregivers and patient advocacy organizations is a vital part of the drug development and review process. However, how that engagement happens can determine how successful it is. This was the key question addressed by the “Practices and Principles: Navigating…

When Mark Dant’s son Ryan was first diagnosed with MPS-I, a rare genetic disorder that leads to organ damage, he had to buy a medical dictionary in order to decipher the words the doctors were saying to him. “I didn’t understand the language of the scientists,” Dant recalled. “The key for every…

“We really need to wake up quickly,” Al Gore told The Washington Post in an interview about the looming food crisis caused by climate change. ...“But technology and science has an important role to play,” Gore stated. Farmers can be part of the climate change solution by cutting greenhouse gas…

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates…

As the world’s largest business aviation trade show takes place in Las Vegas, a Congressional hearing on climate change and clean power convenes on Capitol Hill. Sustainable aviation fuels took center stage at both and was highlighted as one tool that is helping to decarbonize the U.S…

Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors…

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams. That was the unanimous…

Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from the American biotechnology sector and stressing startups that rely on foreign capital to cure disease. That was the message of James Huang, a managing partner in Kleiner Perkins’s China…